Modality
Fusion Protein
MOA
CD47i
Target
PD-L1
Pathway
Angiogenesis
Cervical CaMMNSCLC
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
Jan 2022
→ Sep 2031
Phase 2Current
NCT07004132
2,391 pts·Cervical Ca
2022-01→2031-09·Terminated
NCT08934588
274 pts·NSCLC
2024-02→2026-03·Active
2,665 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-03-182w agoPh3 Readout· NSCLC
2026-11-137mo awayAdCom· Cervical Ca
2031-09-075.4y awayPh3 Readout· Cervical Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Termina…
P2/3
Active
Catalysts
Ph3 Readout
2026-03-18 · 2w ago
NSCLC
AdCom
2026-11-13 · 7mo away
Cervical Ca
Ph3 Readout
2031-09-07 · 5.4y away
Cervical Ca
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07004132 | Phase 2/3 | Cervical Ca | Terminated | 2391 | ACR20 |
| NCT08934588 | Phase 2/3 | NSCLC | Active | 274 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |